Cover Image
市場調查報告書

Cathepsin S (EC 3.4.22.27) :開發中產品分析

Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363132
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
Cathepsin S (EC 3.4.22.27) :開發中產品分析 Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2016
出版日期: 2016年10月12日 內容資訊: 英文 42 Pages
簡介

本報告提供Cathepsin S藥物的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

Cathepsin S概要

治療藥的開發

Cathepsin S:開發中的產品 - 各開發階段

Cathepsin S:開發中的產品 - 治療範圍別

Cathepsin S:開發中的產品 - 各適應症

Cathepsin S:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

Cathepsin S:企業開發中的產品

Cathepsin S:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

Cathepsin S治療藥的開發企業

  • Amura Holdings Limited
  • F. Hoffmann-La Roche Ltd.
  • Fusion Antibodies Limited
  • LEO Pharma A/S
  • Virobay Inc.

Cathepsin S:藥物簡介

Cathepsin S:暫停中的計劃

Cathepsin S:中止開發的產品

Cathepsin S:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0582TDB

Summary

Global Markets Direct's, 'Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2016', provides in depth analysis on Cathepsin S (CTSS or EC 3.4.22.27) targeted pipeline therapeutics.

The report provides comprehensive information on the Cathepsin S (CTSS or EC 3.4.22.27), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cathepsin S (CTSS or EC 3.4.22.27)
  • The report reviews Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cathepsin S (CTSS or EC 3.4.22.27)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cathepsin S (CTSS or EC 3.4.22.27) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cathepsin S (CTSS or EC 3.4.22.27) Overview
  • Therapeutics Development
    • Cathepsin S (CTSS or EC 3.4.22.27) - Products under Development by Stage of Development
    • Cathepsin S (CTSS or EC 3.4.22.27) - Products under Development by Therapy Area
    • Cathepsin S (CTSS or EC 3.4.22.27) - Products under Development by Indication
  • Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Cathepsin S (CTSS or EC 3.4.22.27) - Products under Development by Companies
  • Cathepsin S (CTSS or EC 3.4.22.27) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cathepsin S (CTSS or EC 3.4.22.27) - Companies Involved in Therapeutics Development
    • Amura Holdings Limited
    • F. Hoffmann-La Roche Ltd.
    • Fusion Antibodies Limited
    • Sanofi
    • Virobay Inc.
  • Cathepsin S (CTSS or EC 3.4.22.27) - Drug Profiles
    • AM-3840 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-3876 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fsn-0503h - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-7625 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-5461111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-114137 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBY-036 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBY-129 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBY-285 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBY-50365 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBY-825 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cathepsin S (CTSS or EC 3.4.22.27) - Dormant Projects
  • Cathepsin S (CTSS or EC 3.4.22.27) - Discontinued Products
  • Cathepsin S (CTSS or EC 3.4.22.27) - Featured News & Press Releases
    • Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease
    • Nov 14, 2014: Virobay To Present Data On Two Cathepsin S Inhibitor Programs In Neuropathic Pain And Alzheimer's Disease At The 2014 Society For Neuroscience Annual Meeting
    • May 23, 2013: Virobay Initiates Phase I Trial Of VBY-036 For Treatment Of Neuropathic Pain
    • Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Amura Holdings Limited, H2 2016
  • Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Pipeline by Fusion Antibodies Limited, H2 2016
  • Pipeline by Sanofi, H2 2016
  • Pipeline by Virobay Inc., H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top